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According to the World Health Organisation (WHO), the number of people suffering from 
Alzheimer’s disease (AD) worldwide is around 18 million. The prevalence of AD doubles 
every five years between 65 and 85 years of age and it is estimated that due to the ageing 
population, 34 million people will suffer from AD by 2025. The WHO has also stated that if 
AD onset were delayed by five years, the number of cases worldwide could be halved [1]. 
Currently there are no curative or disease-stalling treatments for AD and a major research 
effort is underway in order to better understand the molecular and cellular details of the 
pathways that result in this devastating neurodegenerative disorder. This is research is critical 
if effective therapeutics are to be developed. 
 
It is a well-known fact that the brain is a lipid-rich organ, with around 50% of its dry mass 
accounted for by lipids [2]. This is largely due to the myelin that ensheathes neuronal axons. 
In addition to the insulating function of myelin lipids it is abundantly clear that there are 
numerous additional pathways by which brain lipid homeostasis may have an impact on (or 
be altered as a consequence of) AD. The functions of lipids in brain cells include regulation 
of signalling, transcription, membrane structure, synaptic function, protein processing, 
protein-protein interactions and more; as will become clear in the brief introduction of the 
articles (below) appearing in this Special Issue of BBA: Molecular and Cellular Biology of 
Lipids dedicated to Lipids and Alzheimer’s disease. 
 
Although keyword searches are an imperfect means of assessing research activity in a 
particular field, it is interesting to note that in the last two decades the number of publications 
containing the searchable terms “lipid and Alzheimer” has increased rapidly compared to the 
number of publications containing each of these terms alone (Fig 1). There appears to be two 
“bursts” of research activity in the “lipids and AD field”. The first was in the early to mid 
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1990’s, a period that coincides with the discovery that APOE genotype is associated with AD 
risk [3], and the second in the early 2000s, a period that coincides with the discovery that (in 
retrospective studies) statin use appears to afford protection for AD [4]. Of course these are 
only examples of research findings that may have sparked further interest in the field; there 
were clearly many exciting developments in the last two decades that may have contributed 
to the escalating interest in the possible role that lipids may play in AD. 
 
The goal of this Special Issue of BBA: Molecular and Cellular Biology of Lipids dedicated to 
Lipids and Alzheimer’s disease is to provide an overview of current developments and new 
ideas that may not yet be fully explored. The contributions are in the form of reviews, 
primary research articles and in some cases a mixture of both. The emphasis for all 
contributions has been to provide current information that points towards future avenues of 
research that should be pursued to better understand the relationships between lipid 
metabolism and AD and, where possible, provide some insight regarding therapeutic targets 
for the disease. The 29 papers included in this Special Issue are loosely grouped into nine 
topics: 1. Genetics, bioinformatics and cutting-edge technology; 2. Phospholipases and fatty 
acids; 3. Apolipoproteins and lipid transport; 4. Cell membranes and endo/lysosomal lipid 
transport; 5. Sphingolipid pathways; 6. Signalling and transcriptional regulation; 7. Lipid 
peroxidation; 8. Lipid changes in Alzheimer’s disease brain; 9. Amyloid-β – lipid 
interactions and cross-talk. An intriguing article reviewing the very early history of the lipid-
AD connection (dating back to the seminal papers by Alois Alzheimer himself) is also 
included. These contributions are briefly summarised below. 
 
1. Genetics, bioinformatics and cutting-edge technology 
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Jones and colleagues outline the rationale and strengths of genome-wide association studies 
(GWAS) and provide a current update of genes, including CLU (clusterin), associated with 
AD risk [5]. A surprisingly large number of genes identified by AD association studies are 
directly involved in lipid pathways and Wollmer has used a bioinformatics approach to 
interrogate the AmiGo gene ontology database and the AlzGene database in order to generate 
a comprehensive listing of genes involved in cholesterol metabolism that may be associated 
with AD risk [6]. Lipidomics has emerged as a powerful technique to identify changes in 
multiple lipid classes simultaneously. The article by Han sets out the principles of mass 
spectrometry-based shotgun lipidomics and goes on to report changes in brain ceramide and 
sulfatide levels in subjects with mild cognitive impairment or AD [7]. 
 
2. Phospholipases and fatty acids 
Specific fatty acids are known to play important roles in neurobiology. Mucke and Sanchez-
Mejia provide an overview of essential fatty acid (EFA) metabolism in the brain and provide 
evidence indicating altered Group IVA phospholipase A2 (GIVA-PLA2) activity may 
contribute to Aβ-induced pathology in AD ([8], and see cover illustration). On a related 
subject, Oster and Pillot provide an overview of the multiple protective actions that one 
specific EFA, docosahexaenoic acid, may exert in the context of Aβ-induced neurotoxicity 
[9]. Oliveira and Di Paolo discuss the role of phospholipase D (PLD) in the brain and suggest 
that that through the regulation of APP processing (and other pathways), PLD isozymes may 
contribute to AD neurodegeneration [10].  
 
3. Apolipoproteins and lipid transport 
One of the seminal findings linking lipids to AD was the identification of the APOE ε4 allele 
as a significant risk factor [3]. Recent studies shed light on the mechanisms by which apoE 
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may modulate AD and these findings are comprehensively reviewed by Vance and Hayashi 
[11]. LaDu and colleagues provide a concise overview of the factors that may be involved in 
lipoprotein remodelling in the parenchyma and highlight the research questions that should 
be addressed in order to better understand the processes regulating lipoprotein metabolism in 
the brain [12]. One area of lipoprotein biogenesis that has attracted attention in the AD 
context is the so-called LXR-ABCA1-APOE regulatory axis. Lefterov and colleagues review 
this area and highlight the important role that ABCA1-mediated apoE lipidation may play in 
regulating Aβ aggregation and clearance [13]. Kågedal and colleagues report that the 
intracellular cholesterol transport protein NPC1 is upregulated in AD hippocampal neurons; a 
finding that is recapitulated in amyloidogenic transgenic mice [14]. Although the 
physiological implications of increased NPC1 expression remain to be resolved, dysregulated 
lysosomal lipid trafficking in AD is an area that appears to warrant further attention.  
 
4. Cell membranes and endo/lysosomal lipid transport 
In an area linked to the lysosomal system, Potier and colleagues provide a review article 
dealing with methods for analysing subcellular changes in membrane cholesterol localization 
and the potential impact this may have on endosome size [15]. A research article by the same 
group reveals that changes in plasma membrane cholesterol levels may regulate clathrin-
mediated APP endocytosis and Aβ production [16]. The topic of intracellular cholesterol 
transport and the impact this has on APP processing is explored further in the comprehensive 
review provided by Burns and Rebeck [17]. This is followed by a detailed review by Vetrivel 
and Thinakaran covering the important role that membrane lipid rafts play in APP processing 
in which particular emphasis is placed on the factors that regulate targeting of APP and the β- 
and γ-secretases to lipid rafts [18]. 
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5. Sphingolipid pathways 
Sphingolipids including sphingomyelin (SM) and glycosphingolipids (GSLs) are a 
component of myelin sheaths and are also highly enriched in lipid raft microdomains within 
cell membranes. Yanagisawa and colleagues review the role that ganglioside GM1 plays in 
the regulation of Aβ conformation and fibrillization [19]. The role that dysfunctional 
sphingolipid metabolism (particularly involving the production of ceramide and other 
bioactive metabolites) may play in regulating synaptic function and neurodegeneration in AD 
is comprehensively reviewed by Haughey and colleagues [20]. An article from my own 
laboratory demonstrates the potential anti-amyloidogenic action of several structurally related 
ceramide analogues that are known inhibitors of GSL synthesis [21]. 
 
6. Signalling and transcriptional regulation 
The crucial function that lipids play in cellular signalling in health and disease is widely 
recognised. Eckert and colleagues provide a detailed overview of the role that isoprenoids 
play in regulating small GTPases and present an argument that alterations in protein 
prenylation may contribute to synaptic dysfunction and other aspects of AD [22]. The 
potential role that an array of biologically active nuclear lipid mediators may play in 
regulating gene transcription and the possible impact that this may have on pathways 
involving oxidative stress, inflammation and apoptosis is brought into the AD context in a 
thought-provoking article by Farooqui and colleagues [23]. Burris and colleagues provide 
evidence that 24-hydroxycholesterol binds to two members of the nuclear hormone receptor 
superfamily, RORα and RORγ, thereby suppressing their constitutive transcriptional activity 
[24]. It is proposed that this may underlie at least a proportion of the protective functions that 
have been previously ascribed to the LXR agonists such as T0901317 and GW3965 in AD 
animal models. 
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7. Lipid peroxidation 
There has been a long-standing interest in the role that lipid peroxidation may play in AD 
pathogenesis. Butterfiled and colleagues provide a detailed overview of the deleterious 
function that the aldehydic lipid peroxidation end-product, 4-hydroxynonenal (HNE), plays 
in AD pathogenesis by virtue of its capacity to derivitize specific amino acid side chains [25]. 
A concise review by Pratico highlights the mechanisms by which isoprostanes are formed in 
the AD brain and the pathways by which these products of arachidonic acid oxidation may 
induce cellular stress [26]. 
 
8. Lipid changes in Alzheimer’s disease brain 
In addition to changes in lipid peroxidation, there is mounting evidence that changes in lipid 
synthesis and metabolism are dysfunctional in the AD brain. Three papers focus on different 
aspects of sterol metabolism in the AD brain. Ledesma and colleagues review the factors that 
lead to altered cholesterol homeostasis in the ageing brain and the implications this has for 
AD pathogenesis and treatment [27]. Kolsch and colleagues provide data indicating levels of 
cholesterol and its precursors lanosterol, lathosterol and desmosterol are reduced in CSF 
derived from AD patients [28]. A study by Marx and colleagues focuses on the neurosteroids 
pregnenolone and dehydroepiandrosterone and show that both of these potentially 
neuroprotective molecules are reduced in AD temporal cortex as compared to control 
subjects [29]. 
 
9. Amyloid-β  – lipid interactions and cross-talk 
Possibly one of the most studied areas relating lipid metabolism to AD concerns the 
relationship (and in some instances the direct interaction) between membrane lipids and 
	   8	  
processing of APP to generate Aβ. Bhattacharyya and Kovacs provide strong evidence 
suggesting that the inhibition of acyl-coenzyme A: cholesterol acyl transferase 1 to prevent 
intracellular cholesteryl ester accumulation may represent a novel strategy to lower Aβ 
generation and accumulation in the AD brain [30]. A review article from Hartmann and 
colleagues provides a detailed overview of the mechanisms by which membrane lipid 
structure may modulate APP processing and an intriguing regulatory feedback loop that 
involves the modulation of lipid homeostasis by APP cleavage products is described [31]. 
Sanders and colleagues describe another recently identified interaction between membrane 
lipid and APP that relies on the direct binding of the APP C99 C-terminal transmembrane 
domain to cholesterol; an interaction that favours C99 localization in lipid rafts thus 
enhancing amyloidogneic processing [32]. 
 
The papers listed in abovementioned sections of this Special Issue of BBA: Molecular and 
Cellular Biology of Lipids dedicated to Lipids and Alzheimer’s disease are prefaced by an 
intriguing historical review article by Foley who examines the very earliest reports describing 
alterations in lipid levels associated with AD pathology [33]. Surprisingly, the earliest papers 
from Alois Alzheimer and others published a century ago dedicate substantial discussion to 
the occurrence of glial lipid inclusions in AD brain sections. It is only relatively recently 
though that powerful genetics studies combined with modern molecular and cell biology 
approaches are revealing the precise details of the pathways that may link lipid pathways 
with AD pathogenesis. The articles briefly introduced above provide a broad cross-section of 
the fertile “Lipids and AD field” which is now providing tangible leads for therapeutic 
exploitation. 
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Figure legend 
 
Figure 1.  Relative number of publications appearing in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) that are identified by the term “Lipid” (blue line), 
“Alzheimer” (green line) or “Lipid and Alzheimer” (red line) are plotted for the period 
covering 1980 to 2009. The 2009 vales are arbitrarily assigned a value of 100. The numbers 
of papers appearing in 2009 in each of the categories were: Lipid, 39,324; Alzheimer 3,702; 
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